<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04349280</url>
  </required_header>
  <id_info>
    <org_study_id>213152</org_study_id>
    <nct_id>NCT04349280</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer</brief_title>
  <official_title>A Phase Ib Trial to Evaluate the Efficacy and Safety of Bintrafusp Alfa Monotherapy in Metastatic or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression or Recurrence Following Treatment With a Platinum Agent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate bintrafusp alfa in participants with metastatic or&#xD;
      locally advanced urothelial cancer. This trial provides the first evaluation of bintrafusp&#xD;
      alfa in participants with urothelial cancer that has progressed following platinum therapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 8, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single arm study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open label study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed overall response rate (ORR) - Investigator assessment</measure>
    <time_frame>From 6 month after Day 1 of treatment through 3 years maximum</time_frame>
    <description>The ORR is defined as the percentage of participants with a partial response (PR) or complete response (CR) as assessed by Investigator using Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) - Investigator assessment</measure>
    <time_frame>From start of treatment up to 3 years</time_frame>
    <description>DOR is defined as the time from first documentation of an objective response (CR or PR) according to RECIST v 1.1 assessed by the investigator to the date of first documentation of objective response of disease progression or death due to any cause whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) - Investigator assessment</measure>
    <time_frame>From start of treatment up to 3 years</time_frame>
    <description>PFS according to RECIST v 1.1 assessed by investigator is defined as the time from first administration of study intervention until date of the first documentation of PD or death due to any cause in the absence of documented PD, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed overall response rate- Independent Review Committee (IRC)</measure>
    <time_frame>From start of treatment up to 3 years</time_frame>
    <description>ORR is defined as the percentage (%) of participants with a PR or CR as assessed by IRC using RECIST v 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response - IRC</measure>
    <time_frame>From start of treatment up to 3 years</time_frame>
    <description>DOR is defined as the time from first documentation of an objective response (CR or PR) according to RECIST v 1.1 assessed by IRC to the date of first documentation of objective response of disease progression or death due to any cause whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival - IRC</measure>
    <time_frame>From start of treatment up to 3 years</time_frame>
    <description>PFS according to RECIST v 1.1 assessed by IRC, is defined as the time from first administration of study intervention until date of the first documentation of PD or death due to any cause in the absence of documented PD, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From start of treatment up to 3 years</time_frame>
    <description>OS is defined as the time from first administration of study intervention to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>From start of treatment up to 3 years</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether considered related to the study intervention. A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, other situations which involve medical or scientific judgment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with AEs by their severity</measure>
    <time_frame>From start of treatment up to 3 years</time_frame>
    <description>The severity of AEs will be graded utilizing the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), v 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration observed immediately at the end of infusion (Ceoi) for bintrafusp alfa</measure>
    <time_frame>Up to 2 years maximum</time_frame>
    <description>Blood sample will be collected for measurement of serum concentrations of bintrafusp alfa for Ceoi analysis at indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration observed immediately before next dosing (corresponding to pre-dose or trough concentration for multiple dosing) (Ctrough) for bintrafusp alfa.</measure>
    <time_frame>Up to 2 years maximum</time_frame>
    <description>Blood sample will be collected for measurement of serum concentrations of bintrafusp alfa for Ctrough analysis at indicated time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with positive anti-drug antibodies (ADAs) against bintrafusp alfa</measure>
    <time_frame>Up to 2 years maximum</time_frame>
    <description>Serum samples will be collected at indicated time points for analysis of ADAs by using tiered testing with validated immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with positive ADAs against bintrafusp alfa</measure>
    <time_frame>Up to 2 years maximum</time_frame>
    <description>Serum samples will be collected at indicated time points for analysis of ADAs.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Participants receiving bintrafusp alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive bintrafusp alfa 1200 milligram (mg), intravenous (IV) infusion, once every 2 weeks (Q2W) until progressive disease (PD), death, unacceptable toxicity, study withdrawal or up to 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bintrafusp alfa</intervention_name>
    <description>Participants will receive bintrafusp alfa 1200 mg, IV infusion, Q2W until PD, death, unacceptable toxicity, study withdrawal or up to 2 years.</description>
    <arm_group_label>Participants receiving bintrafusp alfa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants can give signed informed consent/assent which includes compliance with&#xD;
             the requirements and restrictions listed in the informed consent form (ICF).&#xD;
&#xD;
          -  At least eighteen years of age at the time of signing the informed consent.&#xD;
&#xD;
          -  Participants with histologically confirmed locally advanced or metastatic or locally&#xD;
             advanced/unresectable urothelial carcinoma (including renal, pelvis, ureter, urinary&#xD;
             bladder, urethra). Mixed histologies are acceptable provided transitional cell&#xD;
             carcinoma is the predominant histology. 1. Measurable disease per RECIST v 1.1&#xD;
             criteria; and 2. Experienced PD or recurrence either following platinum containing&#xD;
             chemotherapy for metastatic or locally advanced/unresectable urothelial cancer or&#xD;
             within 12 months from completion of neo-adjuvant or adjuvant platinum-containing&#xD;
             chemotherapy for localized muscle-invasive urothelial cancer.&#xD;
&#xD;
          -  Able to provide, a tumor tissue sample collected during screening and prior to&#xD;
             administration of bintrafusp alfa.&#xD;
&#xD;
          -  Able to provide an archival tumor sample (preferably from the most recent biopsy).&#xD;
             Archival material is formalin fixed tumor tissue sample from a biopsy of a tumor&#xD;
             lesion.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.&#xD;
&#xD;
          -  Participants with adequate organ system functions as defined follows: Absolute&#xD;
             neutrophil count (ANC) &gt;=1.5*10^9 cells per liter (cells/L); Hemoglobin &gt;=9.0 grams&#xD;
             per deciliter (g/dL); Platelets &gt;=100*10^9 cells/L; international normalized ratio&#xD;
             (INR) or prothrombin time (PT) &lt;=1.5*Upper limit of normal (ULN); Albumin &gt;=2.5 g/dL;&#xD;
             Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) &lt;=2.5*ULN or&#xD;
             &lt;=5*ULN for participants with documented liver metastases; Total bilirubin &lt;=1.5*ULN&#xD;
             (Isolated bilirubin &gt;1.5*ULN is acceptable if bilirubin is fractionated and direct&#xD;
             bilirubin &lt;35 percent); calculated creatinine clearance (CrCI) &gt;=30 milliliter per&#xD;
             minute (mL/min) and Ejection Fraction &gt;=50 percent.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  A female is eligible if she is not pregnant or breastfeeding, and at least one of the&#xD;
             following conditions applies: Not a woman of childbearing potential (WOCBP) or If a&#xD;
             WOCBP, use a highly effective contraceptive method (i.e., with a failure rate of &lt;1%&#xD;
             per year), preferably with low user dependency, for the following time periods: Before&#xD;
             the first dose of the study interventions, if using hormonal contraception: has&#xD;
             completed at least one 4-week cycle of an oral contraception pill and either had or&#xD;
             has begun her menses or has used a depot contraceptive or extended-cycle oral&#xD;
             contraceptive for least 28 days and has a documented negative pregnancy test using a&#xD;
             highly sensitive assay; during the intervention period; and after the study&#xD;
             intervention period (i.e., after the last dose of study intervention is administered)&#xD;
             for at least 2 months.&#xD;
&#xD;
          -  The Investigator evaluates the effectiveness of the contraceptive method in&#xD;
             relationship to the first dose of study intervention.&#xD;
&#xD;
          -  Participant has a negative serum or highly sensitive urine pregnancy test, as required&#xD;
             by local regulations, within 24 hours before the first dose of study intervention. If&#xD;
             a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum&#xD;
             pregnancy test is required.&#xD;
&#xD;
          -  The Investigator reviews the medical history, menstrual history, and recent sexual&#xD;
             activity to decrease the risk for inclusion of a female with an early undetected&#xD;
             pregnancy.&#xD;
&#xD;
          -  Male participants: Contraceptive use by men should be consistent with local&#xD;
             regulations regarding the methods of contraception for those participating in clinical&#xD;
             studies. Male participants are eligible to participate if they agree to the following&#xD;
             from the time of first dose of study until 125 days after the last dose of study&#xD;
             treatment to allow for clearance of any altered sperm: Refrain from donating sperm; Be&#xD;
             abstinent from heterosexual intercourse as their preferred and usual lifestyle&#xD;
             (abstinent on long term and persistent basis) and agree to remain abstinent or agree&#xD;
             to use a male condom and female partner to use an additional highly effective&#xD;
             contraceptive method with a failure rate of &lt;1% per year when having sexual&#xD;
             intercourse with a woman of childbearing potential who is not currently pregnant.&#xD;
&#xD;
          -  Archival tumor sample high for Programmed Death-Ligand 1 (PD-L1) by central assay.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active brain and/or leptomeningeal disease that is symptomatic or requires therapeutic&#xD;
             intervention. Participants with asymptomatic central nervous system (CNS) metastases&#xD;
             who are clinically stable as demonstrated by serial brain images and have no&#xD;
             requirement for corticosteroids for at least 14 days prior to enrollment are eligible.&#xD;
&#xD;
          -  History of malignancy other than urothelial cancer within the last 3 years except for&#xD;
             localized tumors that have been treated with curative intent or have not required&#xD;
             therapy in the past 2 years. (e.g., resected non-melanoma skin cancer).&#xD;
&#xD;
          -  No more than 2 lines of systemic therapy for the treatment of metastastic disease. If&#xD;
             the most recent therapy was not a platinum-based regimen, the participant must have&#xD;
             progressed on or after that therapy.&#xD;
&#xD;
          -  Cirrhosis or current unstable liver or biliary disease per investigator assessment&#xD;
             defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia,&#xD;
             esophageal or gastric varices, or persistent jaundice.&#xD;
&#xD;
          -  Current pneumonitis or history of non-infectious pneumonitis that required systemic&#xD;
             immunosuppressive treatment.&#xD;
&#xD;
          -  Active autoimmune disease that required systemic immunosuppressive treatment within&#xD;
             the past 2 years.&#xD;
&#xD;
          -  Received prior allogeneic/autologous bone marrow or solid organ transplant.&#xD;
&#xD;
          -  Receiving systemic corticosteroids (&gt;10 mg daily oral prednisone or equivalent) or&#xD;
             other immunosuppressive agent within 7 days prior to study treatment. Inhaled or&#xD;
             topical steroids are permitted.&#xD;
&#xD;
          -  Known severe hypersensitivity reactions to monoclonal antibodies or any ingredient&#xD;
             used in the study treatment formulation (Grade &gt;=3 NCI-CTCAE v 5.0).&#xD;
&#xD;
          -  Active infection requiring systemic therapy.&#xD;
&#xD;
          -  Received any live vaccine within 30 days prior first dose of intervention.&#xD;
&#xD;
          -  Known history of positive test for human immunodeficiency virus (HIV) with the&#xD;
             exception of participants with cluster of differentiation 4 (CD4) + T-cell (CD4+)&#xD;
             counts &gt;=350 cells per microliter (cells /uL) and no history of acquired&#xD;
             immunodeficiency syndrome (AIDS)-defining opportunistic infections.&#xD;
&#xD;
          -  Active hepatitis B virus (HBV) (HBV surface antigen-positive).&#xD;
&#xD;
          -  Active hepatitis C virus (HCV) infection, or positive HCV antibody, with the exception&#xD;
             of participants that 1. Have HCV viral load below the limits of quantitation and 2.&#xD;
             Completed curative antiviral therapy or are receiving and compliant with antiviral&#xD;
             therapy.&#xD;
&#xD;
          -  History or evidence of cardiac abnormalities within the 6 months prior to first dose&#xD;
             of intervention which include: a. Serious, uncontrolled cardiac arrhythmia or&#xD;
             clinically significant electrocardiogram abnormalities including second degree (Type&#xD;
             II) or third-degree atrioventricular block or QTcF interval &gt;450 millisecond (msec)&#xD;
             (or QTcF &gt;480 msec for participants with bundle branch block); b. Cardiomyopathy,&#xD;
             myocardial infarction, acute coronary syndromes (including unstable angina pectoris),&#xD;
             coronary angioplasty, stenting or bypass grafting; c. Congestive heart failure (Class&#xD;
             II, III, or IV) as defined by the New York Heart Association functional classification&#xD;
             system; and d. Symptomatic pericarditis.&#xD;
&#xD;
          -  Participants with history of bleeding diathesis or recent major bleeding events&#xD;
             considered by the Investigator as high risk for investigational drug treatment are&#xD;
             also excluded.&#xD;
&#xD;
          -  Any other serious or uncontrolled medical disorder that, in the opinion of the&#xD;
             investigator, may increase the risk associated with study participation or study drug&#xD;
             administration, impair the ability of the participant to receive protocol therapy, or&#xD;
             interfere with the interpretation of study results.&#xD;
&#xD;
          -  Received prior systemic anti-cancer therapy within 2 weeks prior to study treatment.&#xD;
&#xD;
          -  Received prior therapy with an anti- programmed death 1 (PD-1), anti-PD-L1,&#xD;
             anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)&#xD;
             antibody (including ipilimumab or any other antibody or drug specifically targeting&#xD;
             T-cell co-stimulation or checkpoint pathways).&#xD;
&#xD;
          -  Received prior therapy targeting transforming growth factor (TGF) beta - (e.g.,&#xD;
             Galunistertib).&#xD;
&#xD;
          -  Received radiation therapy (or other non-systemic disease therapy) within 2 weeks&#xD;
             prior to study treatment.&#xD;
&#xD;
          -  Undergone major surgery within 4 weeks prior to administration of study treatment.&#xD;
&#xD;
          -  Residual toxicities attributed to prior anti-cancer therapy that are clinically&#xD;
             significant or unmanaged and &gt;Grade 1 or previous baseline other than neuropathy&#xD;
             (&lt;=Grade 2), alopecia, and fatigue.&#xD;
&#xD;
          -  The participant has participated in a clinical trial and has received an&#xD;
             investigational product within the following time period prior to the first dosing day&#xD;
             in the current study: 30 days, 5 half-lives or twice the duration of the biological&#xD;
             effect of the investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than 2 investigational anti-cancer medicinal products within 12&#xD;
             months prior to the first dosing day.&#xD;
&#xD;
          -  Is known to abuse alcohol or drugs.&#xD;
&#xD;
          -  Has any psychiatric condition that would prohibit the understanding or rendering of&#xD;
             informed consent or consistent participation in study procedures.&#xD;
&#xD;
          -  Has legal incapacity or limited legal capacity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Galsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shuchi Gulati</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Amir Mortazavi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alexander I. Spira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Petros Grivas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Srikala Sridhar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alain Ravaud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poitiers Cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolas Isambert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Damien Pouessel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yohann Loriot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michiel S. van der Heijden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rafael Morales Barrera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bernard Doger de Spéville</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Castellano Gauna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Begoña Pérez Valderrama</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Powles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bintrafusp Alfa</keyword>
  <keyword>Platinum Agent</keyword>
  <keyword>Response Evaluation Criteria in Solid Tumors</keyword>
  <keyword>Urothelial Cancer</keyword>
  <keyword>M7824</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

